Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Acute 2Leukemia 2Relapsed Pediatric Solid Tumor 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Gastrointestinal Stromal Tumors 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 2nimotuzumab 1Vinorelbine 1Valproic Acid 1Radiotherapy 1Everolimus 1Erlotinib Hydrochloride 1Drug Therapy 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Diffuse Intrinsic Pontine Glioma × Dasatinib × Clear all
NCT02233049 2018-07-23

BIOMEDE

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Unknown
250 enrolled
CNS

Diffuse Intrinsic Pontine Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡